Abstract 16P
Background
Ovarian cancer (OC) is the second gynecological malignancy among women and presents high rates of recurrence associated with chemoresistance. Tumor cells adjust their energy metabolism in favor of their rapid progression. Melatonin (Mel), a hormone produced and secreted by the pineal gland during darkness, has obvious anti-tumor activities. Therefore, we investigated the mechanistic role of Mel on energy metabolism in human OC cells (SKOV-3 and CAISMOV24 cells), with special focus on glycolytic metabolism in addition to cell signaling molecules.
Methods
Cell lines were treated with Mel at concentrations of 3.4 μM for SKOV-3 and 7 μM for CAISMOV24 based on the cell cytotoxicity (CC50) for 24 h; a luzindole-treated group was used to test the influence of melatonin receptors, MT1 and MT2. Protein levels of glycolytic enzymes were analyzed by western blot and kinase levels were measured by multiplex assay.
Results
Melatonin levels dropped by half in the OC cells. We observed a significant decline in the levels of HIF-1α, G6PDH, GAPDH, LDH, and PDH in OC cells treated with melatonin regardless of the presence of luzindole, thus proving its receptor-independent actions; conversely, the luzindole-exposed groups had an upregulation of these proteins. In regard to kinases signaling, SKOV-3 cells treated with melatonin had a reduction in the concentration of CREB, JNK, NF-kB, p-38, ERK1/2, Akt, p70s6k, STAT3, and STAT5, all of them associated with tumor growth, metastasis, and recruitment of oncostatic components. In the CAISMOV24 cells, these molecules were reduced after the combination of melatonin with luzindole.
Conclusions
These findings showed that melatonin potentially regulates energy-related processes in OC cells, thereby favoring the reversal of the Warburg effect, in addition to attenuating cell signaling involved with tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Biosciences of Botucatu.
Funding
CAPES, FAPESP (grant number: 2021/12971-7), CNPq (304108/2020-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
Presenter: Mateusz Iwanski
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract